RPR-122818

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameRPR-122818
Drug Alias NameRPR-122818
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodieterase 4 inhibitorsMatrix metalloproteinase-2 inhibitors
TargetsPhosphodieterase 4Matrix metalloproteinase-2
Therapy Area/IndicationsPsoriasisDermatitis, AtopicMultiple Sclerosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRhone Poulenc Rorer Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRhone Poulenc Rorer Sa
Active IndicationsN/A
Inactive IndicationsPsoriasisDermatitis, AtopicMultiple Sclerosis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A